Atea Pharmaceuticals, Inc. AVIR
Set alert
4.10 USD -0.01 -0.24%
At close · Nov 2
4.10 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
3.95 Day range 4.24
2.87 52-week range 6.45
- YTD
- +14.85%
- 1 year
- +26.15%
- Open
- 4.15
- Prev close
- 4.11
- Mkt cap
- 328.84M
- Vol
- 330.31K
- Avg vol
- 281.81K
- EPS
- -2.09
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.95
- High
- 4.24
- Forward P/E
- -2.12
- Beta
- 0.17
- Short ratio
- 14.25
- Inst. own
- 71.14%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 3.31
- 200-d avg
- 3.59
- 1y target
- 7.40
Analyst view
Consensus: none
Price target (mean) 7.40 +80.5% upside
Now 4.10
- Target (low)
- 6.20
- Target (mean)
- 7.40
- Target (high)
- 8.00
Ratings (0m) 3 1 buy · 1 hold · 1 sell
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell1
Recommendation trend
- This month 3
- 1 month ago 3
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.28963 | -0.38 – -0.13 | -0.47 | +38.4% | 0 | 0.0% | 3 |
| Next quarter | -0.37 | -0.41 – -0.33 | -0.75 | +50.7% | 0 | 0.0% | 2 |
| Current year | -1.81 | -1.98 – -1.50 | -1.63 | -10.7% | 0 | 0.0% | 3 |
| Next year | -1.58 | -1.68 – -1.42 | -1.81 | +12.4% | 0 | 0.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 2024 | Morgan Stanley | Upgrade | Underweight | Equal-Weight |
| Aug 10, 2023 | JP Morgan | Downgrade | Neutral | Underweight |
| Mar 16, 2023 | JP Morgan | Maintained | — | Neutral |
| Jan 27, 2023 | SVB Leerink | Maintained | — | Market Perform |
| Jan 24, 2023 | Morgan Stanley | Maintained | — | Underweight |
| Aug 15, 2022 | Morgan Stanley | Maintained | — | Underweight |
| Mar 2, 2022 | JP Morgan | Maintained | — | Neutral |
| Mar 1, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Feb 16, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Jan 6, 2022 | Morgan Stanley | Downgrade | Equal-Weight | Underweight |
| Nov 18, 2021 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Oct 20, 2021 | SVB Leerink | Maintained | — | Outperform |
| Oct 20, 2021 | JP Morgan | Downgrade | Overweight | Neutral |
| Oct 5, 2021 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Sep 9, 2021 | SVB Leerink | Initiated | — | Outperform |
| Aug 18, 2021 | Morgan Stanley | Maintained | — | Overweight |
| Jun 3, 2021 | Morgan Stanley | Maintained | — | Overweight |
| Apr 6, 2021 | Morgan Stanley | Maintained | — | Overweight |
| Jan 29, 2021 | JP Morgan | Maintained | — | Overweight |
| Nov 25, 2020 | Evercore ISI Group | Initiated | — | Outperform |
| Nov 24, 2020 | JP Morgan | Initiated | — | Overweight |
| Nov 24, 2020 | William Blair | Initiated | — | Outperform |
| Nov 24, 2020 | Morgan Stanley | Initiated | — | Overweight |